A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Effect of Rocatinlimab on Vaccine Antibody Response in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD)
Criteria:Subject has provided informed consent/assent prior to initiation of any study specific activities/procedures.
Age 18 to 54 years.
Subject has a diagnosis of AD (according to American Academy of Dermatology Consensus Criteria [Eichenfield, 2014]) that has been present for at least 6 months before signing of informed consent
AD must be moderate to severe
At least 7% coverage- (1% being on one hand)